Option Care Health to Participate in the BofA Securities Health Care Conference
BANNOCKBURN, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ: OPCH), the nation's largest independent national provider of home and alternate site infusion services, will participate in the BofA Securities Health Care Conference, being held in Las Vegas, on Tuesday, May 14, 2024, including a fireside chat presentation at 2:20pm PT. The webcast will be available online at https://investors.optioncarehealth.com.
About Option Care Health
Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.
For Investor Inquiries:
Mike Shapiro, Chief Financial Officer Option Care Health 312.940.2538 [email protected]
Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET.
A combined audio cast and telephone conference with the opportunity to ask questions will be...
This announcement summarizes Bioretec Ltd's business review for January-March 2024. The complete business review is attached to this release as a PDF file and available on the company's website at...
SHL Telemedicine Ltd. ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it's SmartHeart® membership program in the US.
This...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The...
Author Kory L. Wilson and his family have experienced the benefits of information he shares in Home Remedies: A Guidebook To Breaking Away From Big Pharma ($15.99, paperback, 9781662896668; $6.99, e-book, 9781662896675).
For years, I have collected...
